Domača stranGSK • NYSE
add
GSK plc
58,07 $
Pred odprtjem:(0,72 %)+0,42
58,49 $
Konec trgovanja: 27. feb., 08:25:00 GMT -5 · USD · NYSE · Izjava
Prejšnji trg. dan.
59,54 $
Dnevni razpon
58,05 $ - 59,07 $
Letni razpon
32,38 $ - 61,70 $
Tržna kapitalizacija
118,63 mrd. USD
Povprečni obseg
6,42 mio.
Razm. P/E
15,43
Dividendna donosnost
3,07 %
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (GBP) | dec. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 8,62 mrd. | 6,17 % |
Stroški poslovanja | 4,57 mrd. | −0,28 % |
Čisti dohodek | 636,00 mio. | 53,62 % |
Čista dobičkovnost prihodkov | 7,38 | 44,71 % |
Earnings per share | — | — |
EBITDA | 2,50 mrd. | 35,38 % |
Efektivna davčna stopnja | 23,47 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (GBP) | dec. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 3,41 mrd. | −21,27 % |
Skupna sredstva | 61,12 mrd. | 2,78 % |
Skupne obveznosti | 45,16 mrd. | −2,62 % |
Celoten lastniški kapital | 15,96 mrd. | — |
Shares outstanding | 4,01 mrd. | — |
Razmerje P/B | 14,59 | — |
Donosnost sredstev | 5,87 % | — |
Donosnost kapitala | 10,70 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (GBP) | dec. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 636,00 mio. | 53,62 % |
Denar iz dejavnosti | 2,28 mrd. | −2,19 % |
Denar iz naložb | −933,00 mio. | 16,62 % |
Denar iz financiranja | −856,00 mio. | −1,66 % |
Neto sprememba denarnih sredstev | 448,00 mio. | 19,47 % |
Prost denarni tok | 1,15 mrd. | −49,69 % |
Vizitka
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Generalni direktor
Datum ustanovitve
27. dec. 2000
Spletno mesto
Zaposleni
68.629
